Retatrutide | Triple Agonist Research Peptide
AUD $200
For laboratory research use only. Not for human use.
Research-grade Retatrutide (LY3437943) — the triple GIP/GLP-1/glucagon receptor agonist currently in Phase 3 clinical development. Studied for metabolic disease, obesity, and NASH research. Third-party HPLC tested to ≥98% purity. For laboratory research use only.
Supply Specifications
| Peptide | Retatrutide (LY3437943) |
| Mechanism | Triple GIP/GLP-1/Glucagon receptor agonist |
| Format | Lyophilised powder |
| Purity | ≥98% by HPLC |
| Testing | Third-party HPLC + Mass Spec |
| Storage | -20°C lyophilised |
| Use | Laboratory research use only |
| Price | AUD $200 |
Research Summary
Retatrutide is a once-weekly injectable peptide that simultaneously activates GIP, GLP-1, and glucagon receptors. In Phase 2 clinical trials published in The New England Journal of Medicine (2023), participants receiving the highest dose achieved a mean body weight reduction of 24.2% over 48 weeks — the largest pharmacological weight reduction observed in any clinical trial at that time.
The triple mechanism distinguishes Retatrutide from earlier GLP-1 agonists (Semaglutide) and dual agonists (Tirzepatide). The additional glucagon receptor agonism is hypothesised to increase energy expenditure beyond what GLP-1 or dual agonists can achieve.
Retatrutide is currently in Phase 3 development (TRIUMPH programme) across obesity, type 2 diabetes, and NASH indications. It is not TGA-approved in Australia and is available for laboratory research use only.
Related Research
Disclaimer: All products supplied by PeptideIQ are for laboratory research use only. They are not approved for human use, consumption, or therapeutic application. PeptideIQ complies with all applicable Australian regulations including the Therapeutic Goods Act 1989.